BACKGROUND: Effective cancer biomarkers for early detection, prognosis, or therapy response prediction are urgently needed in ovarian cancer. Kallikrein-related peptidases, including KLK5, have been reported to play an important role in the course of the disease. PATIENTS AND METHODS: KLK5 antigen content was determined by enzyme-linked immunosorbent assay in ovarian cancer patients' [FIGO (International Federation of Gynecology and Obstetrics) stages I-IV, n = 52] serum as well as ascitic fluid and compared with KLK5 content in serum of patients with benign ovarian tumors (n = 45). RESULTS: KLK5 antigen content was significantly elevated in the serum of ovarian cancer patients compared with the serum of patients with benign ovarian tumors. Forty-two of 52 ovarian cancer serum samples, 42 of 43 benign ovarian tumor serum samples, and all 41 ascitic fluid samples were KLK5 positive. Elevated KLK5 antigen in serum and ascitic fluid of ovarian cancer patients was a prognostic factor for progression-free survival. CONCLUSIONS: Our data support the finding that ovarian cancer patients release significant amounts of KLK5 into serum and ascitic fluid but KLK5 antigen is low in serum of patients with benign ovarian tumors. Increased serum and ascitic fluid KLK5 levels are associated with poor patient outcome, thus underlining the importance of KLK5 as a biomarker for early detection as well as for disease management in ovarian cancer.
BACKGROUND: Effective cancer biomarkers for early detection, prognosis, or therapy response prediction are urgently needed in ovarian cancer. Kallikrein-related peptidases, including KLK5, have been reported to play an important role in the course of the disease. PATIENTS AND METHODS: KLK5 antigen content was determined by enzyme-linked immunosorbent assay in ovarian cancerpatients' [FIGO (International Federation of Gynecology and Obstetrics) stages I-IV, n = 52] serum as well as ascitic fluid and compared with KLK5 content in serum of patients with benign ovarian tumors (n = 45). RESULTS:KLK5 antigen content was significantly elevated in the serum of ovarian cancerpatients compared with the serum of patients with benign ovarian tumors. Forty-two of 52 ovarian cancer serum samples, 42 of 43 benign ovarian tumor serum samples, and all 41 ascitic fluid samples were KLK5 positive. Elevated KLK5 antigen in serum and ascitic fluid of ovarian cancerpatients was a prognostic factor for progression-free survival. CONCLUSIONS: Our data support the finding that ovarian cancerpatients release significant amounts of KLK5 into serum and ascitic fluid but KLK5 antigen is low in serum of patients with benign ovarian tumors. Increased serum and ascitic fluid KLK5 levels are associated with poor patient outcome, thus underlining the importance of KLK5 as a biomarker for early detection as well as for disease management in ovarian cancer.
Authors: Julia Dorn; Alexandra Yassouridis; Axel Walch; Eleftherios P Diamandis; Manfred Schmitt; Marion Kiechle; Ping Wang; Enken Drecoll; Barbara Schmalfeldt; Daniela Loessner; Matthias Kotzsch; Viktor Magdolen Journal: Am J Cancer Res Date: 2015-12-15 Impact factor: 6.166
Authors: David Pépin; Zhong-Qi Shao; Geneviève Huppé; Andrea Wakefield; Chee-Wui Chu; Zahra Sharif; Barbara C Vanderhyden Journal: PLoS One Date: 2011-11-15 Impact factor: 3.240
Authors: Julia Dorn; Holger Bronger; Ronald Kates; Julia Slotta-Huspenina; Barbara Schmalfeldt; Marion Kiechle; Eleftherios P Diamandis; Antoninus Soosaipillai; Manfred Schmitt; Nadia Harbeck Journal: Oncol Lett Date: 2014-10-24 Impact factor: 2.967
Authors: Manfred Schmitt; Viktor Magdolen; Feng Yang; Marion Kiechle; Jane Bayani; George M Yousef; Andreas Scorilas; Eleftherios P Diamandis; Julia Dorn Journal: Radiol Oncol Date: 2013-10-08 Impact factor: 2.991